May 18, 2021

To develop drugs that are safe and effective in all populations, it is imperative that studies represent all racial/ethnic groups. Biological markers, socioeconomic barriers, and cultural differences are all critical factors in successful drug development. Clinical trials conducted between 2000 to 2020 played a vital role in the FDA approval of medications we currently use...

There has been a longstanding gender imbalance in the burden of disease affecting female patients with age-related macular degeneration (AMD). Researchers explored the trend patterns of this gender disparity over several decades to determine the extent of this imbalance in disease burden. Using data from the 2017 Global Burden of Disease Study, the researchers collected...

It is crucial that patients with age-related macular degeneration (AMD) are diagnosed early and receive continuous medical care. If not managed adequately, the outcome for patients with AMD is likely poor, and the disease may progress to wet AMD. Researchers sought to determine what socioeconomic barriers may be to blame for patients who are not...

Previous research has shown that wet and dry age-related macular degeneration (AMD) are most prevalent in Caucasian Americans. Asian Americans experience the next highest prevalence rates, followed by Hispanic Americans, and lastly, African Americans. The characteristics and progression of disease also vary based on patient race and ethnicity. Researchers sought to characterize the progression of...